Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. Antagon
2. Ganirelix
3. Ganirelix Diacetate
4. Gnrh, N-ac-2-nal(1)-4-cl-phe(2)-3-pal(3)-et2-harg(6,8)-alanh2(10)-
5. Lhrh, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)-
6. Lhrh,n-ac-2-nal(1)-4-cl-phe(2)-3-pal(3)-et2-harg(6,8)-alanh2(10)-
7. N-ac-(2-naphthyl)ala-2-(4-cl-phe)-3-(3-pyridinyl-ala)-6,8-et2-harg-10-alanh2-lhrh
8. N-acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-(n,n'-diethylamidino)-d-lysyl-l-leucyl-n(sup 6)-(n,n'-diethylamidino)-l-lysyl-l-prolyl-d-alaninamide Diacetate (salt)
9. Orgalutran
10. Rs 26306
11. Rs-26306
12. Rs-26306-298
1. 129311-55-3
2. Ganirelix Acetate [usan]
3. Ganirelix Acetate Injection
4. Antagon
5. 56u7906fqw
6. Orgalutran
7. Rs-26306
8. Ganirelix (acetate)
9. Ganirest
10. D-alaninamide,n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-[bis(ethylamino)methylene]-d-lysyl-l-leucyl-n6-[bis(ethylamino)methylene]-l-lysyl-l-prolyl-, Diacetate (salt)
11. N-acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-(n,n'-diethylamidino)-d-lysyl-l-leucyl-n(sup 6)-(n,n'-diethylamidino)-l-lysyl-l-prolyl-d-alaninamide Diacetate (salt)
12. Rs-26306-298
13. Unii-56u7906fqw
14. Ganirest (tn)
15. Orgalutran Tfa Salt
16. Ganirelix Acetate [mi]
17. Ganirelix Acetate (jan/usan)
18. Ganirelix Acetate [jan]
19. Org-37462
20. Ganirelix Acetate [vandf]
21. Ganirelix Acetate Injection (tn)
22. Ganirelix Acetate [mart.]
23. Ganirelix Acetate [who-dd]
24. Akos025394292
25. Ganirelix Acetate [orange Book]
26. Hy-109532
27. D04302
28. 311g553
29. J-005666
30. Q27261435
31. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-((ethylamino)(ethylimino)methyl)-d-lysyl-l-leucyl-n(sup 6)-((ethylamino)(ethylimino)methyl)-l-lysyl-l-prolyl-, Diacetate (salt)
Molecular Weight | 1690.4 g/mol |
---|---|
Molecular Formula | C84H121ClN18O17 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 48 |
Exact Mass | 1688.8845622 g/mol |
Monoisotopic Mass | 1688.8845622 g/mol |
Topological Polar Surface Area | 526 Ų |
Heavy Atom Count | 120 |
Formal Charge | 0 |
Complexity | 3060 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 10 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Ganirelix acetate |
Drug Label | Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix Acetate is derived from native GnRH with substitutions of amino acids at positions 1,... |
Active Ingredient | Ganirelix acetate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 250mcg base/0.5ml |
Market Status | Prescription |
Company | Organon Usa |
2 of 2 | |
---|---|
Drug Name | Ganirelix acetate |
Drug Label | Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix Acetate is derived from native GnRH with substitutions of amino acids at positions 1,... |
Active Ingredient | Ganirelix acetate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 250mcg base/0.5ml |
Market Status | Prescription |
Company | Organon Usa |
The prevention of premature luteinising-hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques.
In clinical studies, Orgalutran was used with recombinant human follicle-stimulating hormone or corifollitropin alfa, the sustained follicle stimulant.
Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
Hormone Antagonists
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)
H01CC01
H01CC01
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-03-07
Pay. Date : 2024-03-05
DMF Number : 13971
Submission : 1999-02-04
Status : Active
Type : II
NDC Package Code : 60870-0476
Start Marketing Date : 2021-08-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-05-07
Pay. Date : 2020-04-15
DMF Number : 33546
Submission : 2019-12-13
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-08-30
Pay. Date : 2021-07-13
DMF Number : 36108
Submission : 2021-07-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25866
Submission : 2012-03-28
Status : Active
Type : II
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-02-04
Pay. Date : 2015-09-18
DMF Number : 29585
Submission : 2015-07-24
Status : Active
Type : II
NDC Package Code : 35207-0010
Start Marketing Date : 2017-09-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36902
Submission : 2022-04-28
Status : Active
Type : II
NDC Package Code : 42973-325
Start Marketing Date : 2021-10-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-08-04
Pay. Date : 2017-07-27
DMF Number : 30800
Submission : 2016-07-28
Status : Active
Type : II
Registration Number : 230MF10067
Registrant's Address : Hybio Medicine Park, No. 37, Keji C. 2nd St. Shenzhen High-tech Industrial Park, Guangdong, P. R. China 518057
Initial Date of Registration : 2018-05-31
Latest Date of Registration : --
NDC Package Code : 14403-0011
Start Marketing Date : 2019-04-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Women's Healthcare
Currency : USD
2021 Revenue in Millions : 111
2020 Revenue in Millions : 81
Growth (%) : 37
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 123
2021 Revenue in Millions : 111
Growth (%) : 11
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 110
2022 Revenue in Millions : 123
Growth (%) : -11
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?